Key Considerations of Gene Therapy Development: A Caregiver's Story

Emily Walsh Martin, PhD, spoke with Amber Freed, founder and CEO of SLC6A1 Connect, a patient organization focused on accelerating the development of therapies for SLC6A1 patients like her son Maxwell.

Show your support for ASGCT!: https://asgct.org/membership/donate

See omnystudio.com/listener for privacy information.